End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.085 CAD | -10.53% | -5.56% | -15.00% |
01/04 | Willow Biosciences Narrows 2023 Loss YOY | MT |
29/03 | Willow Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Business Summary
Number of employees: 19
Sales per Business
CAD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Research and Development
100.0
%
| 1 | 77.2 % | 1 | 100.0 % | +84.86% |
Sales per region
CAD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1 | 77.2 % | 1 | 100.0 % | +84.86% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chris Savile
CEO | Chief Executive Officer | - | 12/19/12 |
Travis Doupe
DFI | Director of Finance/CFO | - | 12/19/12 |
Trish Choudhary
CTO | Chief Tech/Sci/R&D Officer | - | 01/19/01 |
Simon Hickling
PRN | Corporate Officer/Principal | - | - |
Sony Gill
SEC | Corporate Secretary | 48 | 12/19/12 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jim Lalonde
CHM | Chairman | 63 | 21/23/21 |
Donald Archibald
BRD | Director/Board Member | 63 | 12/19/12 |
Director/Board Member | 51 | 12/19/12 | |
Raffi Asadorian
BRD | Director/Board Member | 54 | 11/23/11 |
Chris Savile
CEO | Chief Executive Officer | - | 12/19/12 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 126,950,810 | 92,241,495 ( 72.66 %) | 0 | 72.66 % |
Company contact information
Willow Biosciences, Inc.
1201 5th Street South West Suite 202
T2R 0Y6, Calgary
+
http://www.willowbio.comSector
Sales per Business
Sales per region
1st Jan change | Capi. | |
---|---|---|
-15.00% | 8.81M | |
-3.79% | 87.06B | |
+1.45% | 40.25B | |
-15.94% | 31.09B | |
+52.66% | 24.74B | |
-14.50% | 15.91B | |
-9.12% | 11.96B | |
-14.38% | 11.92B | |
-42.56% | 11.61B | |
+4.87% | 8.73B |
- Stock Market
- Equities
- WLLW Stock
- Company Willow Biosciences Inc.